Bambusa Therapeutics Inc, a clinical-stage biotechnology company developing next-generation bispecific antibodies for immunology and inflammation (I&I), announced on Thursday the appointment of Todd James as executive vice president, chief financial officer (CFO).

Bambusa says that James's appointment strengthens its financial leadership and expands its executive team as the company advances its clinical pipeline and executes its long-term growth strategy.

James brings more than 20 years of senior leadership experience in the biopharmaceutical industry, with expertise in capital markets, investor relations, and corporate strategy. He most recently served as senior vice president of corporate affairs and investor relations, and was a member of the executive leadership team at two publicly traded biotechnology companies: Acceleron Pharma, prior to its USD11.5bn acquisition by Merck, and Viridian Therapeutics.